albiglutide + sulfonylurea

**Albiglutide + sulfonylurea** is a combination therapy used in adults with type 2 diabetes mellitus, involving the co-administration of albiglutide, a once-weekly injectable glucagon-like peptide 1 (GLP-1) receptor agonist, and a sulfonylurea, a class of oral hypoglycemic drugs. Albiglutide works by mimicking GLP-1 to stimulate insulin secretion in a glucose-dependent manner, suppress glucagon secretion, and slow gastric emptying, which leads to improved glycemic control and some weight loss. Sulfonylureas increase pancreatic insulin secretion to lower blood glucose. Clinical trials have investigated albiglutide in combination with sulfonylureas, typically in patients with inadequate glycemic control on other antidiabetic agents, and have demonstrated reductions in HbA1c and fasting plasma glucose; however, the risk of hypoglycemia increases when combined, particularly in the presence of a sulfonylurea. The combination is not associated with a unique brand name but is utilized as a therapeutic option under clinical guidelines for managing type 2 diabetes[1][2][4].

Brand names

TanzeumEperzan

Other names

albiglutidesulfonylurea